The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626001079336p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
30/03/2026
Date registered
Help: Date registered
1/09/2026
Date last updated
Help: Date last updated
1/09/2026
Date data sharing statement initially provided
Help: Data sharing statement date
1/09/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluating the efficiency of dosimetry following radioisotope therapy in patients with metastatic cancer.
Scientific title
PRELuDE: A Prospective, open-label, single centre, single arm, unblinded study Evaluating Lutetium-177 Dosimetry Efficiency in patients with metastatic prostate cancer
Additional trial identifiers [1] 316909 0
Nil
Universal Trial Number (UTN)
Trial acronym
PRELuDE
Related trial records

Health condition
Health condition(s) studied:
Castrate resistant metastatic prostate cancer 341329 0
prostate cancer 341330 0
Condition category
Condition code
Cancer 337399 337399 0 0
Prostate
Public Health 337908 337908 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
We propose to introduce routine clinical prospective radionuclide treatment planning for personalized precision theranostic oncology.

Standard treatment of metastatic castrate resistant prostate cancer (mCRPC) worldwide is 177Lutetium PSMA radioligand therapy administered as an arbitrary fixed activity of 7400 – 8500 Megabecquerels (MBq) for 4-6 cycles 6-8 weeks apart. Half the patients are estimated to be either undertreated or overtreated by this standard regimen. Furthermore, it has been recently shown that two thirds of the radiation absorbed dose to tumour is delivered within the first two cycles.

We aim to change practice by prescription of tumour radiation absorbed dose in Gray (Gy) prospectively in each patient in order to optimize treatment planning, analogous to routine external beam radiation oncology practice.

The PRELuDE study will utilize tracer administration of 1000 MBq 177Lu-PSMA to each patient, with subsequent measurement by serial semi-quantitative, radiomic imaging measurement of individual tumour radiation absorbed dose (Gy) while taking into account radiation dose limitations for organ toxicity.

Tracer studies of 1000 MBq 177Lu-PSMA have been reported in isolated studies comparing tumour of uptake of different radiopharmaceuticals in prostate cancer patients which have demonstrated their feasibility.

The preliminary validation phase will be performed in 20 patients, each of whom will complete the initial two cycles of their Lu177-PSMA standard activity therapy. Each of this patient cohort will receive a prospective tracer activity of 1000 MBq and then undergo imaging with a gamma camera for 30- 60 minutes at 4 hours, 1 day and 3-5 days post injection. Image results will be semi-quantitative and qualitatively assessed from the whole body planar and SPECT-CT images acquired at the aforementioned 3 time points. The calculated BED will then be compared with that measured from repeated SPECT-CT routine radiomic imaging at 4 hours, 1 day and 3-5 days after IV administration of 7400-8500 MBq of 177Lu-PSMA therapeutic administration.

Comparison of tracer predicted tumour BED and that actually delivered by therapeutic administration will be used to validate the tracer methodology. Thus determining whether predicting an effective therapeutic radiation absorbed dose prospectively in each individual patient is possible.
Intervention code [1] 333619 0
Diagnosis / Prognosis
Intervention code [2] 334006 0
Treatment: Drugs
Description of the comparator or control
The imaging acquired post administration of 1000 MBq 177Lu-PSMA will be compared with the imaging acquired post administration of 7400-8500 MBq of 177Lu-PSMA therapy. The images will be assessed qualitatively and semi-quantitatively to determine whether tracer administration predicts BED post therapy.
Control group
Active

Outcomes
Primary outcome [1] 344917 0
To determine whether tracer dosimetry will accurately predict biologically effective dose (BED) of the therapeutic administration of Lu177-PSMA .
Timepoint [1] 344917 0
4 hours, 1 day and 3-5 days post injection (of both tracer dose and radioligand therapy).
Secondary outcome [1] 459758 0
No secondary endpoints
Timepoint [1] 459758 0
No secondary endpoints

Eligibility
Key inclusion criteria
1. At least 18 years of age.
2. Metastatic adenocarcinoma of the prostate defined by:
• Documented histopathology of prostate adenocarcinoma (without any features of neuroendocrine carcinoma) OR
• A clinical diagnosis based on PSA elevation and typical imaging findings for metastatic prostate cancer
3. Castration-resistant prostate cancer (defined as disease progressing despite castration by orchidectomy or ongoing luteinising hormone-releasing hormone agonist or antagonist).
4. Disease progression with rising PSA defined by PCWG3 criteria (sequence of 2 rising values at a minimum of 1-week intervals).
5. Disease progression after at least one taxane chemotherapy in the mCRPC setting AND at least one novel androgen receptor signaling inhibitor (in the setting of either mCSPC or mCRPC). Patients with prostate cancer that has a known BRCA mutation must have had at least one PARP inhibitor therapy. If BRCA status is unknown patients will be eligible for inclusion.
6. Imaging evidence of metastatic disease documented with standard imaging.
7. Significant PSMA avidity on 68Ga-PSMA PET/CT, defined as SUVmax >15 at a single site (regardless of lesion size) and SUV max >10 at sites of disease =10mm (unless subject to factors explaining a lower uptake, e.g. respiratory motion, reconstruction artefact) without FDG discordance. Metastases subject to these criteria are for soft tissue disease (not bone metastases), and lymph node measurement taken from the short axis.
8. ECOG performance status:
• 0-2.
9. Adequate renal function:
• Creatinine clearance = 40mL/ min (defined by either Cockcroft-Gault formula or by nuclear medicine renal scan).
10. Adequate liver function:
• Bilirubin < 1.5 x upper limit of normal (ULN) (or if bilirubin is between 1.5 - 2x ULN, must have a normal conjugated bilirubin).
• AST or ALT less than or equal to 2.0 x ULN (or less than or equal to 5.0 x ULN in the presence of liver metastases).
11. Adequate bone marrow function:
• Platelets greater than or equal to 100 x109/L.
• Haemoglobin greater than or equal to 90g/L (no red blood cell transfusion in last 4 weeks).
• Neutrophils > 1.5 x109/L.
12. Estimated life expectancy > 12 weeks.
13. Study treatment both planned and able to start within 21 days.
14. Willing and able to comply with all study requirements (additional imaging time points, tracer Lu177-PSMA injection).
15. Signed, written, informed consent.
Minimum age
18 Years
Maximum age
No limit
Sex
Males
Healthy volunteers
No
Key exclusion criteria
1. Prostate cancer with known significant sarcomatoid, or spindle cell, or neuroendocrine small cell components, or metastasis of other cancer to the prostate.
2. Site(s) of disease that are FDG-positive with minimal PSMA expression defined as FDG intensity > 68Ga-PSMA activity OR 68Ga-PSMA SUVmax < 10
3. Prior treatment with any PSMA-targeted radiotherapy.
4. Concurrent illness, including severe infection that may jeopardise the ability of the participant to undergo the procedures outlined in this protocol with reasonable safety.
5. Pre-existing G3+ toxicities not resolved to G2 or lower before day of randomisation.
6. Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule, including alcohol dependence or drug abuse.
7. Men in sexual relationships with women of reproductive potential who are each not willing/able to use medically acceptable forms of barrier contraception.

Study design
Purpose of the study
Diagnosis
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA

Funding & Sponsors
Funding source category [1] 321504 0
Hospital
Name [1] 321504 0
Fiona Stanley Hospital
Country [1] 321504 0
Australia
Primary sponsor type
Hospital
Name
Fiona Stanley Hospital
Address
Country
Australia
Secondary sponsor category [1] 324266 0
None
Name [1] 324266 0
Address [1] 324266 0
Country [1] 324266 0

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320036 0
WA Health Central HREC
Ethics committee address [1] 320036 0
Ethics committee country [1] 320036 0
Australia
Date submitted for ethics approval [1] 320036 0
13/04/2026
Approval date [1] 320036 0
Ethics approval number [1] 320036 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149222 0
Dr Richard Gauci
Address 149222 0
Fiona Stanley Hospital, 11 Robin Warren Dr, MURDOCH WA 6150
Country 149222 0
Australia
Phone 149222 0
+61086152222
Fax 149222 0
Email 149222 0
Contact person for public queries
Name 149223 0
Richard Gauci
Address 149223 0
Fiona Stanley Hospital, 11 Robin Warren Dr, MURDOCH, WA 6150
Country 149223 0
Australia
Phone 149223 0
+61086152222
Fax 149223 0
Email 149223 0
Contact person for scientific queries
Name 149224 0
Richard Gauci
Address 149224 0
Fiona Stanley Hospital, 11 Robin Warren Dr, MURDOCH, WA 6150
Country 149224 0
Australia
Phone 149224 0
+61086152222
Fax 149224 0
Email 149224 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Not intended for external use



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.